Furthermore, therapies targeting the vascular endothelial growth factor (VEGF) pathway, used to treat solid tumors, can lead to cardiovascular effects such as hypertension and myocardial hypoperfusion, contributing to the development of heart failure. This evidence concerns the gene VEGFA and Hypertension.